OBJECTIVE: Analysis of tumor-infiltrating lymphocytes (TILs) is one of the cornerstones for the understanding of immune responses prevailing in the tumor microenvironment. We studied TILs from squamous cell carcinoma of the cervix ex vivo without proliferating them in vitro before analysis. METHODS: Whereas TILs were magnetic activated cell separation enriched and flow sorted into CD4 CD25 (regulatory T cells [Tregs]), CD4 CD25 (effector T cells [Teffs]) were directly purified by flow cytometry, and both these subsets were characterized phenotypically and functionally. Tissue sections were probed for interleukin 4 (IL-4) and interferon γ. RESULTS: Effector T cells constitutively expressed both interferon γ and IL-4 prototypical cytokines of TH1 and TH2, respectively, and were able to proliferate and secrete higher quantities of both cytokines in response to anti-CD3/anti-CD28 and autologous tumor lysates. Only 53% of cervical cancer Tregs were FOXP3, elaborated transforming growth factor β1, and IL-10 and were able to inhibit both T helper subsets. CONCLUSIONS: Intratumoral Teffs represented functionally active subsets of both TH1 and TH2 that were not anergic but were suppressed by multiple Treg subsets, which comprised FOXP3 + Tregs and Tregs secreting transforming growth factor β1 and IL-10. These results imply that the microenvironment of cervical carcinomas harbored both TH1 and TH2 subsets of CD4 Teffs that were functionally active but were perhaps unable to perform because of the overpowering effect of Tregs.
OBJECTIVE: Analysis of tumor-infiltrating lymphocytes (TILs) is one of the cornerstones for the understanding of immune responses prevailing in the tumor microenvironment. We studied TILs from squamous cell carcinoma of the cervix ex vivo without proliferating them in vitro before analysis. METHODS: Whereas TILs were magnetic activated cell separation enriched and flow sorted into CD4CD25 (regulatory T cells [Tregs]), CD4CD25 (effector T cells [Teffs]) were directly purified by flow cytometry, and both these subsets were characterized phenotypically and functionally. Tissue sections were probed for interleukin 4 (IL-4) and interferon γ. RESULTS: Effector T cells constitutively expressed both interferon γ and IL-4 prototypical cytokines of TH1 and TH2, respectively, and were able to proliferate and secrete higher quantities of both cytokines in response to anti-CD3/anti-CD28 and autologous tumor lysates. Only 53% of cervical cancer Tregs were FOXP3, elaborated transforming growth factor β1, and IL-10 and were able to inhibit both T helper subsets. CONCLUSIONS: Intratumoral Teffs represented functionally active subsets of both TH1 and TH2 that were not anergic but were suppressed by multiple Treg subsets, which comprised FOXP3 + Tregs and Tregs secreting transforming growth factor β1 and IL-10. These results imply that the microenvironment of cervical carcinomas harbored both TH1 and TH2 subsets of CD4 Teffs that were functionally active but were perhaps unable to perform because of the overpowering effect of Tregs.
Authors: Hana Park; Jae Hyung Jung; Min Kyung Jung; Eui-Cheol Shin; Simon Weonsang Ro; Jeon Han Park; Do Young Kim; Jun Yong Park; Kwang-Hyub Han Journal: Hepatol Int Date: 2020-02-18 Impact factor: 6.047
Authors: Marta E Bull; Jillian Legard; Kenneth Tapia; Bess Sorensen; Susan E Cohn; Rochelle Garcia; Sarah E Holte; Robert W Coombs; Jane E Hitti Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Kirvis Torres-Poveda; Margarita Bahena-Román; Claudia Madrid-González; Ana I Burguete-García; Víctor Hugo Bermúdez-Morales; Oscar Peralta-Zaragoza; Vicente Madrid-Marina Journal: World J Clin Oncol Date: 2014-10-10
Authors: Simone Punt; Marjolein E van Vliet; Vivian M Spaans; Cornelis D de Kroon; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova Journal: Cancer Immunol Immunother Date: 2015-03-21 Impact factor: 6.968
Authors: Stéphanie A Demoulin; Joan Somja; Anaëlle Duray; Samuel Guénin; Patrick Roncarati; Philippe O Delvenne; Michael F Herfs; Pascale M Hubert Journal: Oncoimmunology Date: 2015-03-19 Impact factor: 8.110
Authors: Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Jan Woś; Paweł Papież; Marcin Mochocki; Piotr Morawski; Renata Kopta; Magdalena Bryś Journal: Contemp Oncol (Pozn) Date: 2013-10-07